Stastical analysis (I) Meningioma (Disease control) – M=38.382, SD=6.287, p<0.0001 (II) Grade I (Untreated)–M=57.498, SD=3.677(Treated), M=41.847, SD=5.468, p<0.0001 (III) Grade II (Untreated)–M=60.17, SD=2.46, (Treated) M=55.34, SD=0.8067, p<0.0001 (IV) Grade III (Untreated)–M=69.690, SD=3.763, (Treated) M=68.302, SD=3.358, p>0.05. (V) Grade IV (Untreated)–M=72.788, SD=4.063, (Treated) M=70.472, SD=3.520, p>0.05. *M: Mean; SD: Standard Deviation

Figure 7b: Estimation of Bcl2 expression in tumor cell by Flocytometry in all four grades of human glioma. Comparative study were made between untreated and T11TS treated peripheral macrophages in all four grades of glioma. Mean ± SD is based upon six meningioma, twenty each of grade I to IV glioma samples. Meningioma were used as disease control. Significant enhancement in Bax expression were observed in T11TS treated cells of grade I and II glioma. No such significant change reported between T11TS treated and non treated groups of grade III and IV glioma.